Benefits seen there may not generalize to non-diabetic populations
Dosing schedules for GLP-1 medications are established through clinical trials that evaluate efficacy, safety, and patient adherence
Study Selection The trials we included met the following criteria: (1) RCTs that compared GLP-1 receptor agonist with a placebo or active control (other antidiabetic drugs or insulin), (2) patients with type 2 diabetes, type 1 diabetes, prediabetes, overweight or obesity, (3) with durations of at least 24 weeks, and (4) reported the occurrence of at least one case of various thyroid disorders as adverse events
While compounded medications are not FDA-approved in the same way brand drugs are, 503A compounders meet rigorous quality, sterility, and safety standards
If you want a comprehensive medical workup before starting medication, you should look elsewhere